Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in atypical hemolytic uremic syndrome in China
NCT05876351Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2023
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of eculizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Alexion Pharmaceuticals. Started Jul 2023; status: completed.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT05876351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05876351.